Trump Administration Selects 15 Drugs for Medicare Price Negotiations
CMS names 15 drugs, including Trulicity and Biktarvy, for Medicare price negotiations that will take effect in 2028.
Overview
The Trump administration said Tuesday that Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz selected 15 drugs, including Trulicity, Biktarvy and Botox, for Medicare price negotiations that will take effect in 2028.
CMS said about 1.8 million Medicare Part B or Part D enrollees used the 15 drugs in the past year and that the medicines accounted for about 6% of total Part B and Part D spending, making the negotiations potentially significant for taxpayer savings.
AARP CEO Dr. Myechia Minter-Jordan called the announcement a "significant step forward" in a statement, while PhRMA Executive Vice President of Policy and Research Elizabeth Carpenter said in a statement that the Inflation Reduction Act "continues to show why government price setting is the wrong approach," reflecting competing reactions.
CMS said this third round will bring the program to a total of 40 drugs with negotiated prices and that this year marks the first inclusion of Medicare Part B drugs, records show.
Drugmakers have until Feb. 28 to decide whether to participate and, according to CMS, negotiated prices will go into effect in 2028 while the Type 2 diabetes drug Tradjenta will undergo renegotiation.
Analysis
Center-leaning sources present the Medicare negotiation announcement straightforwardly, emphasizing facts, scope and context rather than advocacy. They report who benefits, list affected drugs, and include competing source content — administration praise and industry criticism — without loaded editorial language, relying on quotes and spending figures to let readers weigh the implications.
Sources (3)
FAQ
The selected drugs are: Anoro Ellipta, Biktarvy, Botox and Botox Cosmetic, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz and Xeljanz XR, and Xolair.
Negotiated prices will become effective on January 1, 2028.
This is the first time Medicare Part B drugs, such as those administered in doctor's offices, are eligible for price negotiations, in addition to Part D drugs.
Drugmakers have until February 28, 2026, to decide whether to participate in the negotiations.
The 15 drugs were used by about 1.8 million Medicare Part B or Part D enrollees in the past year and accounted for about 6% of total Part B and Part D spending.
History
This story does not have any previous versions.